Neuroprogression: Pathways to progressive brain changes in bipolar disorder

International Journal of Neuropsychopharmacology

Volumn 12, Issue 4, 2009, Pages 441-445

  Berk, Michael ^a,b,c,d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ORYGEN RESEARCH CENTRE   (Australia)

^c BARWON HEALTH   (Australia)

^d FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

LITHIUM; VALPROIC ACID; NEUROPROTECTIVE AGENT; TRANQUILIZER;

BIPOLAR DISORDER; DISEASE COURSE; DNA METHYLATION; HUMAN; NEUROPROTECTION; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT RESPONSE; ARTICLE; BRAIN; DRUG EFFECT; PATHOLOGY;

ANTIMANIC AGENTS; BIPOLAR DISORDER; BRAIN; DISEASE PROGRESSION; HUMANS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS;

EID: 67649199656     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145708009498     Document Type: Review

References (44)

1. Andreazza AC, Cassini C, Rosa AR, Leite MC, de Almeida LM, Nardin P, Cunha AB, Cereser KM, Santin A, Gottfried C, et al. (2007). Serum S100B and antioxidant enzymes in bipolar patients. Journal of Psychiatric Research 41, 523-529.
2. APA (2000). Diagnostic and Statistical Manual of Mental Disorders (text revision, 4th edn). Washington, DC: American Psychiatric Association.
3. Bai O, Chlan-Fourney J, Bowen R, Keegan D, Li X-M (2003). Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. Journal of Neuroscience Research 71, 127-131.
4. Bai O, Zhang H, Li X-M (2004). Antipsychotic drugs clozapine and olanzapine upregulate bcl-2 mRNA and protein in rat frontal cortex and hippocampus. Brain Research 1010, 81-86.
5. Berk M, Copolov DL, Dean O,LuK,JeavonsS,Schapkaitz I, Anderson-Hunt M, Bush AI (2008a). N-Acetyl cysteine for depressive symptoms in bipolar disorder - a double-blind randomized placebo-controlled trial. Biological Psychiatry 64, 468-475.
6. Berk M, Dodd S, Callaly P, Berk L, Fitzgerald P, de Castella AR, Filia S, Filia K, Tahtalian S, Biffin F, et al. (2007a). History of illness prior to a diagnosis of bipolar disorder or schizoaffective disorder. Journal of Affective Disorders 103, 181-186.
7. Berk M, Hallam KT, McGorry PD (2007b). The potential utility of a staging model as a course specifier: A bipolar disorder perspective. Journal of Affective Disorders 100, 279-280.
8. Berk M, Ng F, Dean O, Dodd S, Bush AI (2008b). Glutathione: a novel treatment target in psychiatry. Trends in Pharmacological Sciences 29, 346-351.
9. Brady K, Goldberg JF (1996). Substance abuse and bipolar disorder. 9th Annual US Psychiatric and Mental Health Congress, 14-17 November 1996.
10. Chen G, Huang LD, Jiang YM, Manji HK (1999). The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. Journal of Neurochemistry 72, 1327-1330.
11. Conus P, McGorry PD (2002). First-episode mania: a neglected priority for early intervention. Australian and New Zealand Journal of Psychiatry 36, 158-172.
12. El-Badri S, Ashton C, Moore P, Marsh V, Ferrier I (2001). Electrophysiological and cognitive function in young euthymic patients with bipolar affective disorder. Bipolar Disorder 3, 79-87.
13. Franchini L, Zanardi R, Smeraldi E, Gasperini M (1999). Early onset of lithium prophylaxis as a predictor of good long-term outcome. European Archives of Psychiatry and Clinical Neuroscience 249, 227-230.
14. Goldberg JF, Ernst CL (2002). Features associated with the delayed initiation of mood stabilizers at illness onset in bipolar disorder. Journal of Clinical Psychiatry 63, 985-991.
15. Gould TD, Manji HK (2005). Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 30, 1223-1237.
16. Hawton K, Sutton L, Haw C, Sinclair J, Harriss L (2005). Suicide and attempted suicide in bipolar disorder: a systematic review of risk factors. Journal of Clinical Psychiatry 66, 693-704.
17. Holsboer F (2008). En route to personalized antidepressant medicines. International Journal of Neuropsychopharmacology 11 (Suppl 1) 1.
18. Kapczinski F, Vieta E, Andreazza AC, Frey BN, Gomes FA, Tramontina J, Kauer-Sant'Anna M, Grassi-Oliveira R, Post RM (2008). Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neuroscience & Biobehavioral Reviews 32, 675-692.
19. Kauer-Sant'AnnaM,KapczinskiF, Andreazza AC, Bond DJ, Lam RW, Young LT, Yatham LN (2008). Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. International Journal of Neuropsychopharmacology. Published online: 4 September 2008. doi:10.1017/S1461145708009310.
20. Kessing LV, Andersen PK, Mortensen PB (1998). Predictors of recurrence in affective disorder: a case register study. Journal of Affective Disorders 49, 101-108.
21. Kim YK, Jung HG, Myint AM, Kim H, Park SH (2007). Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. Journal of Affective Disorders 104, 91-95.
22. Klein PS, Melton DA (1996). A molecular mechanism for the effect of lithium on development. Proceedings of the National Academy of Sciences USA 93, 8455-8459.
23. Kraepelin E (1921). Manic Depressive Insanity and Paranoia. Bristol: Thoemmes Press.
24. Lopez C, Cortez V, Palacio C, Gallo A, Lopera J, Garcia J (2008). Effect of chronicity on the cognitive performance of patients with bipolar disorder type 1. 3rd Biennial Conference of the International Society of Bipolar Disorders. Delhi India, 27-28 January 2008.
25. Lyoo IK, Sung YH, Dager SR, Friedman SD, Lee JY, Kim SJ, Kim N, Dunner DL, Renshaw PF (2006). Regional cerebral cortical thinning in bipolar disorder. Bipolar Disorder 8, 65-74.
26. Malhi GS, Valenzuela M, Wen W, Sachdev P (2002). Magnetic resonance spectroscopy and its applications in psychiatry. Australian and New Zealand Journal of Psychiatry 36, 31-43.
27. Malhi GS, Yatham LN (2007). Mania matters! Acta Psychiatrica Scandinavica 116 (s434), 1-2.
28. Manji HK, Moore GJ, Rajkowska G, Chen G (2000). Neuroplasticity and cellular resilience in mood disorders. Molecular Psychiatry 5, 578-593.
29. Martinowich K, Manji HK, Lu B (2007). New perspective of BDNF cell biology and its implications in depression. Nature Neuroscience 10, 1089-1093.
30. Matza LS, Rajagopalan KS, Thompson CL, De Lissovoy G (2005). Misdiagnosed patients with bipolar disorder: comorbidities, treatment patterns, and direct treatment costs. Journal of Clinical Psychiatry 66, 1432-1440.
31. McGorry PD, Hickie IB, Yung AR, Pantelis C, Jackson HJ (2006). Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Australian and New Zealand Journal of Psychiatry 40, 616-622.
32. Moore GJ, Bebchuk JM, Hasanat K, Chen G, Seraji-Bozorgzad N, Wilds IB, Faulk MW, Koch S, Glitz DA, Jolkovsky L, Manji HK (2000a). Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects? Biological Psychiatry 48, 1-8.
33. Moore GJ, Bebchuk JM, Wilds IB, Chen G, Manji HK (2000b). Lithium-induced increase in human brain grey matter. Lancet 356, 1241-1242.
34. Ng F, Berk M, Dean O, Bush AI (2008). Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. International Journal of Neuropsychopharmacology 11, 851-876.
35. Post RM (1992). Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. American Journal of Psychiatry 149, 999-1010.
36. Post RM (2007). Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neuroscience & Biobehavioral Reviews 31, 858-873.
37. Robinson LJ, Ferrier N (2006). Evolution of cognitive impairment in bipolar disorder: a systematic review of cross-sectional evidence. Bipolar Disorders 8, 103-116.
38. Roy-Byrne P, Post RM, Uhde TW, Porcu T, Davis D (1985). The longitudinal course of recurrent affective illness: life chart data from research patients at the NIMH. Acta Psychiatrica Scandinavica (Suppl.) 317, 1-34.
39. Scott J, Paykel E, Morriss R, Bentall R, Kinderman P, Johnson T, Abbott R, Hayhurst H (2006). Cognitive-behavioural therapy for severe and recurrent bipolar disorders: Randomised controlled trial. British Journal of Psychiatry 188, 313-320.
40. Strakowski SM, DelBello MP, Zimmerman ME, Getz GE, Mills NP, Ret J, Shear P, Adler CM (2002). Ventricular and periventricular structural volumes in first- versus multiple-episode bipolar disorder. American Journal of Psychiatry
41. Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD (1999). Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in mania. American Journal of Psychiatry 156, 1264-1266.
42. Wadee AA, Kuschke RH, Wood LA, Berk M, Ichim L, Maes M (2002). Serological observations in patients suffering from acute manic episodes. Human Psychopharmacology 17, 175-179.
43. WHO (2005). International Statistical Classification of Diseases and Related Health Problems (ICD-10), 2nd edn. Geneva: Nonserial Publications.
44. Zis AP, Grof P, Webster M, et al. (1980). Prediction of relapse in recurrent affective disorder. Psychopharmacology Bulletin 16, 47-49.